ASP-6432

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameASP-6432
Drug Alias NameASP-6432
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLysophosphatidic acid receptor Edg-2 antagonists
TargetsLysophosphatidic acid receptor Edg-2
Therapy Area/IndicationsProstatic Hyperplasia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstellas Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstellas Pharma Inc
Active IndicationsN/A
Inactive IndicationsProstatic Hyperplasia

Other Information

ATC CodeN/A
Related LinksN/A